Biocon Q1 Review - Covid-19 Related Challenges Drags The Quarter: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Biocon Ltd. posted below par numbers for Q1 FY22.
While revenues were below estimates due to Covid-related operational challenges at active pharmaceutical ingredient facilities, profitability was lower due to a below expected operational performance and share of loss from Bicara Therapeutics.
Revenues grew 5.3% YoY to Rs 1760.6 crore (our estimate: Rs 1895 crore).
Biosimilars grew 9.6% YoY to Rs 758 crore, better than our estimates of Rs 706 crore.
Biocon's research services segment grew 41% YoY at Rs 595 crore, in line with our estimates of Rs 590 crore.
Generic sales de-grew 18.8% YoY to Rs 486 crore (our estimate: Rs 599 crore) due to Covid-related operational challenges at API facilities.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.